Oslo, 15 July 2025: Reference is made to the stock exchange announcement
published by Navamedic ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") on
23 June 2025, regarding Navamedic entering into an asset purchase agreement for
the acquisition of the business of dne pharma AS for a total consideration of up
to NOK 225 million, whereby NOK 185 million is payable at closing, and the
remaining NOK 40 million is payable in two tranches subject to achievement of
certain agreed sales volumes for the acquired products (the "Transaction").

Navamedic is pleased to announce that the Transaction has today been
successfully completed.

The Acquisition encompasses dne pharma's business, including product portfolio,
key employees and all essential contracts of the business, intellectual
property, licenses, and distribution agreements. The product portfolio includes
prominent products such as Ventizolve® (intranasal naloxone spray for opioid
overdose reversal), Levopidon® (levomethadone), and Metadon Dne (methadone) for
opioid substitution therapy. The acquired business will be integrated into
Navamedic's existing commercial platform, enabling rapid market access and
geographic expansion across the Nordics and selected European markets.

"This acquisition represents a significant step in our strategic expansion into
the rapidly growing field of addiction treatment and is well aligned with our
long-term growth ambitions. Thanks to the strong collaboration among all parties
involved, the transaction was completed in a smooth and efficient manner. We are
pleased that the General Meeting unanimously approved the Rights Issue
yesterday, and we are sincerely grateful for the continued support of Kistefos
and the other underwriters," said Kathrine Gamborg Andreassen, CEO of Navamedic.

The Acquisition is financed through a combination of new debt in the amount of
NOK 110 million from Nordea Bank Abp, filial i Norge ("Nordea") and a rights
issue approved at an extraordinary general meeting of Navamedic on 14 July (the
"Rights Issue"). Navamedic has been assisted by DNB Carnegie a part of DNB Bank
ASA ("DNB Carnegie") and Advokatfirmaet Thommessen ("Thommessen") in connection
with the Acquisition, and Navamedic has been granted a bridge loan from Nordea
enabling completion of the Acquisition before completion of the Rights Issue.
Navamedic has retained DNB Carnegie, and Nordea Corporate Finance, a part of
Nordea Bank Abp, filial i Norge as managers and Thommessen as legal advisors for
the Rights Issue.

"We are very pleased closing this transaction with Navamedic and we are
confident that the Navamedic team will continue to grow the opioid substitution
business developed by dne pharma, in particular the Ventizolve® products" says
Geir Ove Engeset, CEO of dne pharma as.

For further information, please contact:

Lars Hjarrand, CFO, Mobile: +47 917 62 842 E-mail: Lars.Hjarrand@navamedic.com,
or
Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880 E-mail:
kathrine@navamedic.com.

About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to
empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and
requirements of the countries where we are present. Our local insight and
competence enable us to understand the specific needs of each country where we
operate and ultimately to gain market access. This makes us a preferred partner
for international companies expanding their footprint across the Nordics and
Benelux regions, through either in-licensing or out-licensing. Navamedic has
been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is
headquartered in Oslo, Norway. For more information, please visit
www.Navamedic.com

Aboutdne pharma/Pharma Production

Prior to closing of the Transaction, dne pharmawas a Norwegian developer and
distributor of addiction and pain therapies, including opioid substitution
treatments and emergency overdose medications. dne pharma's wholly owned
subsidiary, Pharma Production AS, will continue to manufacture and supply the
product portfolio recently acquired by Navamedic, as well as concentrate on
contract manufacturing and development services, including analytical services,
supporting the long-term need for national pharmaceutical production capacity.
https://pharmaproduction.no (https://eur02.safelinks.protection.outlook.com/?url
=
https%3A%2F%2Fpharmaproduction.no%2F&data=05%7C02%7Cole.henrik.eriksen%40navamed
i
c.com%7C4a5078d22d7d47a7384e08ddc37340f3%7Ca5635f8e246b48e094e8806923fb2a69%7C0%
7
C0%7C638881621997591634%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIw
L
jAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=q
y
wslRKXkTVBe7yNmRJjZ2hkA9pxdsfG2qFLSu41gA8%3D&reserved=0).

This information is subject to the disclosure requirements pursuant to Section 5
-12 the Norwegian Securities Trading Act.